Novo Holdings, the holding and investment company that is responsible for managing the assets and wealth of Novo Nordisk, has agreed to acquire Catalent for an upfront payment of $11 billion. The transaction, announced Feb. 5, is expected to close at the end of calendar year 2024. Hellerup, Denmark-based Novo Holdings was advised by Goodwin Procter and a Davis Polk & Wardwell corporate team including partners William H. Aaronson and Shanu Bajaj. Catalent, which is based in Somerset, New Jersey, was represented by a Skadden, Arps, Slate, Meagher & Flom team including partners Todd Freed, Page Griffin, Richard Grossman, Patrick Lewis and Maria Raptis. Jones Day guided the board of directors of Catalent. Sullivan & Cromwell represented Evercore, acting as an independent financial adviser to Novo Nordisk. The Sullivan & Cromwell team included partners Stephen M. Kotran, Jeremy Kutner and Lee C. Parnes.
Biotech & Pharmaceuticals
February 06, 2024, 10:00 AM